- Report
- January 2024
- 278 Pages
Global
€4767EUR$4,995USD£3,994GBP
- Report
- January 2024
- 84 Pages
United States
€1193EUR$1,250USD£1,000GBP
- Report
- November 2018
- 80 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- March 2025
- 115 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 119 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- May 2022
- 100 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP
- Report
- January 2024
- 338 Pages
Global
From €3665EUR$3,840USD£3,071GBP
- Report
- May 2023
- 249 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Report
- July 2022
- 176 Pages
Global
From €3298EUR$3,456USD£2,764GBP
- Report
- February 2022
- 183 Pages
Global
From €3543EUR$3,712USD£2,968GBP
- Book
- April 2023
- 2000 Pages
- Book
- April 2018
- 312 Pages
- Book
- March 2017
- 2008 Pages
- Book
- February 2024
- 640 Pages
- Book
- September 2023
- 288 Pages
- Book
- September 2023
- 288 Pages
- Book
- October 2019
- 632 Pages

The Cancer Care market within the context of Oncology Drugs is a rapidly growing industry. It is composed of a variety of products and services, including drugs, diagnostics, and treatments. Oncology drugs are used to treat cancer, and they can be divided into two categories: targeted therapies and immunotherapies. Targeted therapies are designed to target specific cancer cells, while immunotherapies are designed to boost the body's own immune system to fight cancer. Both types of drugs are used to treat a variety of cancers, including breast, lung, and colorectal cancer.
The Cancer Care market is highly competitive, with many companies vying for market share. Companies in the market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. These companies are all involved in the development, manufacture, and marketing of oncology drugs. Additionally, there are many smaller companies that specialize in the development of new treatments and therapies. Show Less Read more